discoveri
rna
interfer
rnai
mammalian
cell
creat
new
class
therapeut
base
revers
silenc
specif
diseasecaus
gene
therapeut
potenti
depend
abil
deliv
induc
rnai
shortinterf
rna
sirna
microrna
mirna
cell
target
tissu
chapter
review
variou
challeng
deliveri
strategi
sirna
particular
focu
develop
lipid
nanoparticl
lnp
deliveri
technolog
current
lnp
deliveri
system
advanc
technolog
system
deliveri
sirna
numer
formul
variou
stage
clinic
trial
also
discuss
method
improv
gene
silenc
potenc
lnpsirna
well
applic
lnp
technolog
beyond
sirna
encapsul
nucleic
acid
mrna
cluster
regularli
interspac
short
palindrom
repeat
crispr
sinc
demonstr
rna
interfer
rnai
mammalian
model
system
much
interest
arisen
util
variou
promot
rnai
shortinterf
rna
sirna
microrna
mirna
treatment
diseas
rnai
endogen
process
eukaryot
cell
use
rna
molecul
catalyz
degrad
specif
complementari
messeng
rna
mrna
sequenc
possibl
mechan
protect
foreign
pathogen
virus
long
doublestrand
rna
introduc
cell
larg
nucleas
rnaseiii
famili
known
dicer
filipowicz
jaskiewicz
kolb
pillai
cleav
rna
shorter
fragment
approxim
nucleotid
long
fragment
shortinterf
rna
sirna
bernstein
caudi
hammond
hannon
load
rnainduc
gene
silenc
complex
risc
rand
ginalski
grishin
wang
complex
compris
mani
differ
protein
one
protein
argonaut
respons
unwind
sirna
degrad
sens
passeng
strand
matranga
tomari
shin
bartel
zamor
rand
petersen
du
wang
singlestrand
antisens
strand
allow
risc
complex
activ
seek
mrna
complementari
antisens
strand
sirna
amer
martinez
schroeder
mrna
bound
antisens
strand
sirna
mediat
cleavag
mrna
nucleotid
end
antisens
strand
tomari
zamor
risc
complex
seek
degrad
addit
mrna
lead
remark
silenc
target
gene
zamor
theori
sirna
abl
specif
block
synthesi
protein
respons
diseas
howev
actual
translat
sirna
clinic
use
hamper
sever
major
difficulti
includ
need
protect
sirna
degrad
nucleas
biolog
fluid
deliveri
sirna
target
tissu
intracellular
deliveri
sirna
target
cell
cytoplasm
rnai
take
place
lipid
nanoparticl
lnp
lead
deliveri
system
enabl
therapeut
potenti
sirna
system
applic
sempl
et
al
zimmermann
et
al
lnpsirna
system
contain
optim
ioniz
cation
lipid
exhibit
remark
vivo
potenc
silenc
liver
hepatocyt
target
gene
dose
low
sirnakg
bodi
weight
follow
intraven
iv
inject
rodent
jayaraman
et
al
sempl
et
al
therapeut
indic
mice
approach
system
rel
nontox
demonstr
promis
clinic
util
review
challeng
sirna
deliveri
differ
strategi
deliv
sirna
focu
lnp
system
formul
method
also
discuss
current
lnpsirna
formul
clinic
test
import
note
technolog
product
lnp
system
restrict
sirna
also
applic
plasmid
dna
mrna
potenti
cluster
regularli
interspac
short
palindrom
repeat
crispr
dna
versatil
would
pave
way
translat
nucleic
acidbas
therapeut
clinic
would
also
expand
current
arsen
nucleic
acid
therapeut
deliveri
sirna
therapeut
purpos
hamper
sever
major
hurdl
first
nake
sirna
unstabl
rapidli
degrad
nucleas
biolog
fluid
choung
kim
kim
park
choi
layzer
mccaffrey
tanner
huang
kay
shown
chemic
modif
nucleic
acid
omethyl
sproat
lamond
beijer
neuner
ryder
fluoropyrimidin
pieken
olsen
bensel
aurup
eckstein
phosphothio
linkag
chowrira
burk
protect
sirna
nucleas
degrad
second
sirna
penetr
cell
membran
enter
cytoplasm
due
larg
size
rang
kda
neg
charg
de
fougerol
vornloch
maraganor
lieberman
whitehead
langer
anderson
moreov
despit
evid
nake
sirna
taken
endocytosi
neuron
cell
face
addit
challeng
escap
endocytosisbas
degrad
mediat
effect
rnai
lingor
michel
final
system
administ
sirna
accumul
liver
kidney
fail
accumul
site
diseas
braasch
et
al
glomerular
filtrat
pore
size
roughli
nm
nake
sirna
remov
circul
kidney
excret
huang
et
al
deliveri
vehicl
therefor
necessari
overcom
hurdl
realiz
potenti
sirna
therapeut
despit
challeng
accumul
evid
suggest
sirna
deliv
local
tissu
without
use
sophist
deliveri
system
one
simplest
strategi
administ
unprotect
free
sirna
therapeut
purpos
directli
local
tissu
shown
intranas
administr
free
sirna
p
protein
respiratori
syncyti
viru
rsv
parainfluenza
viru
local
sirna
lung
day
inhibit
subsequ
infect
two
virus
bitko
musiyenko
shulyayeva
barik
furthermor
sirna
show
effect
antivir
properti
administ
rsv
infect
best
therapeut
respons
observ
sirna
administ
time
viral
infect
bitko
et
al
notabl
antivir
effect
sirna
complex
transfect
reagent
transittko
miru
bio
madison
wi
significantli
better
nake
form
chemic
modifi
sirna
target
nucleocapsid
protein
rsv
intranas
deliveri
sinc
develop
alnylam
pharmaceut
cambridg
sirna
formul
name
effect
inhibit
rsv
administ
either
prophylact
therapeut
alvarez
et
al
phase
ii
clinic
trial
demonstr
safe
provid
modest
protect
rsv
infect
compar
placebo
treatment
devincenzo
et
al
devincenzo
et
al
anoth
exampl
clinic
applic
intranas
administ
sirna
sar
coronaviru
shown
allevi
sarslik
symptom
rhesu
macaqu
li
et
al
eye
anoth
popular
tissu
local
administr
sirna
agerel
macular
degener
diseas
character
develop
choroid
neovascular
cnv
eye
intravitr
inject
nake
sirna
vascular
endotheli
growth
factor
vegf
receptor
shown
decreas
extent
cnv
mice
shen
et
al
sirna
local
ganglion
layer
retina
h
inject
mrna
level
vegf
receptor
significantli
reduc
day
inject
intravitr
dose
low
sirna
enough
suppress
develop
laserinduc
cnv
mice
shen
et
al
similar
studi
intravitr
inject
sirna
target
erythropoietin
effect
reduc
neovascular
induc
hypoxia
nonhuman
primat
model
laserinduc
cnv
intravitr
dose
sirna
target
vegf
suppress
develop
cnv
day
laser
induct
tolentino
et
al
presenc
bloodbrain
barrier
make
extrem
difficult
drug
especi
larg
molecul
sirna
reach
central
nervou
system
blood
compart
direct
administr
therefor
prefer
rout
drug
entri
shown
sirna
directli
administ
either
intraventricular
intrathec
rout
mediat
gene
silenc
brain
intraventricularli
inject
sirna
shown
mediat
gene
silenc
enhanc
green
fluoresc
protein
egfp
dopamin
transport
serotonin
transport
brain
thakker
et
al
thakker
et
al
also
intrathec
administ
sirna
target
painrel
cation
channel
shown
reduc
express
pain
percept
treat
mice
dorn
et
al
despit
success
exampl
mani
tissu
bodi
remain
inaccess
local
administr
system
deliveri
drug
tissu
would
requir
use
appropri
deliveri
system
one
simplest
earliest
exampl
system
deliveri
sirna
conjug
cholesterol
onto
end
sens
passeng
strand
sirna
soutschek
et
al
intraven
administr
cholesterolconjug
sirna
apolipoprotein
b
apob
effect
decreas
level
apob
mrna
liver
well
plasma
apob
protein
serum
cholesterol
soutschek
et
al
modif
ribos
phosphothio
sirna
backbon
offer
gener
protect
sirna
hydrolysi
nucleas
modif
sirna
avail
review
elsewher
de
fougerol
et
al
kanasti
dorkin
vega
anderson
whitehead
et
al
effect
uptak
cholesterolconjug
sirna
hepatocyt
mediat
via
associ
serum
lipoprotein
wolfrum
et
al
moreov
reconstitut
cholesterolconjug
sirna
purifi
mous
high
densiti
lipoprotein
hdl
show
higher
gene
silenc
efficaci
free
cholesterolconjug
sirna
wolfrum
et
al
other
also
demonstr
mimet
lipoprotein
particl
prepar
recombin
apolipoprotein
apolipoprotein
effect
deliv
cholesterolconjug
sirna
liver
mediat
effect
gene
silenc
nakayama
et
al
exampl
highlight
import
endogen
lipoprotein
mediat
uptak
cholesterolconjug
sirna
inde
later
reveal
lnpsirna
also
depend
lipoprotein
pathway
effect
uptak
liver
cholesterol
conjug
deliveri
strategi
specif
design
sirna
cation
polym
initi
use
deliv
plasmid
dna
antisens
oligonucleotid
later
appli
sirna
polyethylenimin
pei
polycation
polym
wide
use
condens
nucleic
acid
transfectioncompet
polyplex
baker
et
al
utsuno
zheng
et
al
shown
polyplex
pei
sirna
target
nmethyldaspart
nmda
receptor
reduc
express
receptor
decreas
pain
percept
rat
follow
intrathec
administr
tan
yang
shih
lan
cheng
administr
sirna
signific
reduct
nmda
receptor
mrna
observ
day
protein
level
nmda
receptor
suppress
day
tan
et
al
addit
condens
nucleic
acid
pei
shown
protect
sirna
degrad
serum
nucleas
kim
et
al
mahato
kumar
sharma
scheul
et
al
urbanklein
werth
abuharbeid
czubayko
aigner
pei
also
demonstr
efficaci
mean
administr
intraven
administr
polyplex
pei
sirna
vegf
shown
intratumour
local
polyplex
well
silenc
vegf
mice
schiffel
et
al
xenograft
mous
tumor
model
intraperiton
inject
peisirna
target
receptor
led
downregul
express
inhibit
tumor
growth
urbanklein
et
al
despit
success
toxic
high
molecular
weight
pei
kda
kda
remain
major
hurdl
clinic
applic
tseng
mozumdar
huang
zintchenko
philipp
dehshahri
wagner
cyclodextrin
polym
cdp
anoth
popular
cation
polym
use
deliveri
sirna
vivo
cyclodextrin
monom
compris
five
eight
glucopyranos
molecul
link
togeth
ring
linkag
kanasti
et
al
cyclodextrin
monom
join
togeth
linker
contain
cation
amidin
group
bind
nucleic
acid
includ
sirna
gonzalez
hwang
davi
mix
plasmid
dna
cdp
shown
selfassembl
spheric
complex
approxim
nm
diamet
gonzalez
et
al
hwang
bellocq
davi
interact
cdp
particl
plasma
compon
prevent
coat
particl
surfac
polyethylen
glycol
peg
conjug
adamantan
hydrophob
moieti
form
inclus
complex
cyclodextrin
insert
cyclodextrin
core
davi
et
al
target
ligand
transferrin
coupl
adamantanepeg
target
cdp
nanoparticl
specif
cell
bellocq
pun
jensen
davi
davi
et
al
mous
model
ewe
sarcoma
transferrinadamantanepeg
cdp
nanoparticl
abl
reduc
metastat
tumor
size
three
consecut
daili
dose
mgkg
sirna
hulieskovan
heidel
bartlett
davi
trich
although
measur
innat
immun
respons
toxic
liver
kidney
observ
tumor
volum
rebound
soon
cessat
treatment
hulieskovan
et
al
anoth
studi
cdp
nanoparticl
also
show
signific
sign
toxic
innat
immun
respons
cynomolgu
monkey
dose
mgkg
sirna
howev
kidney
liver
damag
well
elev
level
proinflammatori
cytokin
observ
sirna
dose
mgkg
heidel
et
al
final
phase
clinic
trial
involv
melanoma
patient
cdp
nanoparticl
contain
sirna
ribonucleotid
reductas
subunit
effect
reduc
mrna
protein
level
tumor
davi
et
al
addit
pei
cyclodextrin
synthet
polym
chitosan
poli
lacticcoglycol
acid
also
intens
investig
potenti
sirna
deliveri
vivo
patil
swaminathan
sadhukha
panyam
et
al
yuan
naguib
wu
comparison
cation
polym
lipid
nanoparticl
lnp
current
matur
technolog
enabl
deliveri
sirna
vivo
least
four
formul
lnpsirna
variou
phase
clinic
trial
treatment
hypercholesterolemia
transthyretinmedi
amyloidosi
liver
cancer
allen
culli
lnp
exhibit
potent
gene
silenc
activ
hepatocyt
dose
low
mg
sirnakg
bodi
weight
mice
mg
sirnakg
nonhuman
primat
follow
singl
iv
inject
jayaraman
et
al
approxim
time
effect
exampl
pei
cyclodextrin
deliveri
system
mention
furthermor
recent
clinic
result
indic
lnpsirna
system
provid
prolong
suppress
human
transthyretin
singl
dose
mg
sirnakg
bodi
weight
full
recoveri
occur
day
current
gold
standard
potenc
sirnabas
drug
coelho
et
al
follow
section
discuss
variou
formul
method
lead
edg
deliveri
system
current
develop
encapsul
technolog
sirna
stem
earli
work
liposom
small
molecul
deliveri
earli
alec
bangham
colleagu
realiz
lecithin
egg
yolk
phosphatidylcholin
assembl
concentr
lamella
dispers
water
bangham
horn
later
report
lipid
vesicl
capabl
maintain
concentr
gradient
ion
disrupt
addit
deterg
bangham
standish
watkin
bangham
standish
weissmann
studi
properti
lipid
vesicl
intensifi
soon
discoveri
quickli
realiz
physic
properti
vesicl
osmot
swell
abil
trap
solut
includ
ion
glucos
qualit
similar
cell
membran
sessa
weissmann
lipid
vesicl
initi
term
bangasom
due
discoveri
alec
bangham
howev
term
liposom
adopt
subsequ
sessa
weissmann
one
first
applic
liposom
model
biolog
membran
bangham
colleagu
demonstr
liposom
expos
anesthet
permeabl
ion
johnson
miller
bangham
subsequ
liposom
wide
use
drug
deliveri
vehicl
potenti
liposom
drug
carrier
recogn
soon
discoveri
earli
gregori
gregoriadi
one
pioneer
recogn
drug
deliveri
potenti
liposom
appli
enzym
replac
therapi
gregoriadi
leathwood
ryman
gregoriadi
ryman
system
made
hydrat
dri
lipid
film
aqueou
buffer
contain
enzym
amyloglucosidas
albumin
result
encapsul
effici
extrem
poor
less
origin
enzym
protein
encapsul
encapsul
antibiot
penicillin
actinomycin
also
poor
gregoriadi
major
breakthrough
improv
drug
encapsul
effici
liposom
came
develop
transmembran
ph
gradient
load
techniqu
entrap
weakli
basic
drug
accomplish
three
differ
method
figur
first
ph
gradient
gener
hydrat
lipid
film
low
ph
buffer
follow
buffer
exchang
use
solut
neutral
ph
figur
demonstr
weakli
basic
compound
catecholamin
concentr
insid
liposom
acid
interior
nichol
deamer
later
shown
drug
weak
base
doxorubicin
could
also
accumul
high
amount
insid
liposom
acid
interior
mayer
balli
hope
culli
encapsul
drug
respons
transmembran
ph
gradient
readili
explain
neutral
ph
weakli
basic
drug
mixtur
proton
membraneimperm
form
dh
deproton
membraneperm
form
deproton
form
drug
readili
diffus
across
membran
becom
proton
dh
trap
insid
liposom
ph
lower
pk
drug
figur
equilibrium
drug
concentr
gradient
mirror
proton
gradient
thu
ph
gradient
unit
result
higher
drug
concentr
insid
liposom
exterior
medium
standard
ph
gradient
method
lipid
film
first
hydrat
buffer
low
ph
typic
citrat
buffer
ph
follow
extrus
gener
larg
unilamellar
vesicl
ph
gradient
gener
exchang
extern
buffer
buffer
higher
ph
typic
hepe
ph
weakli
basic
drug
enter
vesicl
neutral
form
becom
proton
trap
acid
interior
vesicl
b
ammonium
sulfat
method
transmembran
ammonium
sulfat
gradient
first
gener
hydrat
extrud
lipid
buffer
contain
ammonium
sulfat
follow
exchang
extern
buffer
interior
vesicl
acidifi
neutral
nh
exit
vesicl
leav
behind
proton
process
ph
gradient
use
encapsul
weakli
basic
drug
c
ionophor
method
transmembran
gradient
mg
mn
first
gener
ionophor
coupl
export
mg
import
two
proton
therefor
acidifi
interior
vesicl
chelat
mg
edta
usual
requir
remov
mg
transport
vesicl
second
method
load
weakli
basic
drug
accomplish
use
ammonium
sulfat
bolotin
et
al
scenario
ph
gradient
gener
encapsul
ammonium
sulfat
insid
liposom
follow
exchang
extern
buffer
figur
b
equilibrium
posit
charg
ammonium
ion
nh
neutral
ammonia
nh
exist
insid
liposom
sinc
lipid
membran
highli
permeabl
uncharg
nh
one
proton
remain
insid
liposom
nh
travel
concentr
gradient
outsid
liposom
result
acidif
liposom
interior
figur
b
load
weak
base
drug
respons
ph
gradient
result
interior
drug
concentr
high
nanocryst
drug
form
lead
characterist
coffe
bean
appear
electron
micrograph
abraham
et
al
use
ionophor
offer
third
method
gener
ph
gradient
need
encapsul
weakli
basic
drug
fensk
et
al
transmembran
gradient
dival
cation
mn
mg
first
gener
prepar
liposom
solut
mnso
mgso
follow
exchang
extern
buffer
sucros
solut
gener
dival
cation
gradient
weakli
basic
drug
ionophor
ethylenediaminetetraacet
acid
edta
ad
larg
unilamellar
vesicl
luv
ionophor
coupl
transport
one
dival
cation
luv
import
two
proton
result
acidif
vesicl
interior
figur
c
fensk
et
al
export
dival
cation
chelat
edta
drug
enter
vesicl
method
show
high
level
encapsul
vincristin
ciprofloxacin
drug
retent
properti
similar
ph
gradient
load
method
fensk
et
al
goal
use
liposom
drug
deliveri
vehicl
enhanc
potenc
drug
reduc
side
effect
increas
deliveri
site
diseas
avoid
healthi
tissu
mani
studi
note
vasculatur
site
diseas
tumor
site
infect
site
inflamm
leakier
healthi
tissu
skinner
tutton
brien
steinberg
konerd
streffer
exampl
neovasculatur
form
tumor
lack
smooth
muscl
wall
normal
vasculatur
rel
permeabl
particl
diamet
larger
yuan
et
al
yuan
et
al
result
longcircul
liposom
diamet
nm
preferenti
escap
region
tumor
result
larg
increas
amount
drug
deliv
tumor
addit
lymphat
drainag
tumor
often
impair
caus
liposom
retain
interstiti
space
maeda
combin
phenomenon
call
enhanc
permeat
retent
epr
effect
maeda
maeda
wu
sawa
matsumura
hori
import
note
encapsul
drug
avail
target
cell
must
releas
liposom
exert
effect
certain
drug
rate
drug
releas
strongli
influenc
anticanc
potenc
formul
particularli
true
cell
cyclespecif
drug
vincristin
mayer
et
al
webb
harasym
masin
balli
mayer
achiev
optim
therapeut
activ
rate
drug
releas
control
chang
lipid
composit
liposom
charroi
allen
vari
drugtolipid
ratio
johnston
et
al
serum
lipoprotein
shown
play
critic
role
circul
lifetim
cellular
uptak
lipid
nanoparticl
shown
apolipoprotein
apoai
apoaiv
apo
bind
surfac
neutral
phospholipid
liposom
bisgaier
siebenka
william
particular
apo
apoai
apoaiv
shown
mediat
cellular
uptak
liposom
hepatocyt
vitro
bisgaier
et
al
similarli
apo
shown
mediat
hepat
uptak
blood
clearanc
neutral
liposom
vivo
yan
et
al
apo
apolipoprotein
found
surfac
cholesterolenrich
lipoprotein
chylomicron
verylow
densiti
lipoprotein
vdl
high
densiti
lipoprotein
hdl
mahley
mahley
ji
uptak
lipoprotein
hepatocyt
mediat
receptormedi
endocytosi
low
densiti
lipoprotein
ldl
receptor
ldl
receptor
ldlr
relat
protein
scaveng
receptor
bi
beisiegel
weber
ihrk
herz
stanley
krieger
herz
mahley
ji
role
apo
mediat
hepatocellular
uptak
lnpsirna
system
compris
ioniz
cation
lipid
demonstr
vivo
use
apoedefici
mice
author
demonstr
ioniz
lnp
uptak
hepatocyt
silenc
hepat
gene
factor
vii
greatli
reduc
apoedefici
mice
compar
wildtyp
anim
result
similar
ldlr
mice
lack
ldlr
mediat
hepatocellular
uptak
lnp
interestingli
efficaci
lnp
apoedefici
mice
rescu
conjug
target
ligand
nacetylgalactosamin
galnac
onto
peg
lipid
lnp
galnac
bind
asialoglycoprotein
receptor
express
surfac
hepatocyt
high
affin
provid
altern
pathway
lnpsirna
enter
hepatocyt
apoedefici
mice
contrast
lnp
compos
perman
posit
charg
cation
lipid
seem
depend
apo
liver
uptak
gene
silenc
efficaci
vivo
lower
ioniz
lnp
unlik
entrap
solubl
drug
neutral
liposom
cation
lipid
essenti
effici
encapsul
nucleic
acid
lipid
formul
without
cation
lipid
result
poor
encapsul
antisens
oligonucleotid
maclachlan
use
cation
lipid
first
describ
felgner
cowork
felgner
et
al
use
perman
posit
charg
cation
lipid
n
propyl
n
n
ntrimethylammonium
chlorid
dotma
mediat
cellular
transfect
dna
posit
charg
cation
lipid
facilit
encapsul
anion
nucleic
acid
via
electrostat
interact
cation
lipid
also
provid
posit
surfac
charg
lnp
promot
close
associ
lnp
neg
charg
cell
surfac
shown
cell
surfac
proteoglycan
sialic
acid
interact
cation
liposom
facilit
cellular
uptak
via
endocyt
pathway
mislick
baldeschwiel
mounk
zhong
ciprespalacin
heath
deb
stamatato
leventi
zuckermann
silviu
wrobel
collin
follow
endocytosi
cation
lipid
lnp
hypothes
form
membran
disrupt
ion
pair
anion
lipid
endosom
therebi
facilit
intracellular
releas
nucleic
acid
hafez
maurer
culli
howev
posit
charg
liposom
rapidli
elimin
mononuclear
phagocyt
system
mp
litzing
perman
charg
cation
lipid
highli
toxic
sever
limit
vivo
applic
audouy
de
leij
hoekstra
molema
liebert
et
al
scheul
et
al
zhang
liu
huang
avoid
toxic
issu
ioniz
cation
lipid
primari
secondari
tertiari
amin
headgroup
appar
pk
valu
less
seven
develop
purpos
encapsul
nucleic
acid
lipid
posit
charg
ph
valu
pka
eg
ph
almost
neutral
lnp
physiolog
ph
valu
first
ioniz
cation
lipid
use
encapsul
nucleic
acid
propan
dodap
sempl
et
al
pka
bailey
culli
antisens
oligonucleotid
lnp
contain
dodap
exhibit
rel
long
circul
lifetim
follow
iv
administr
expect
lipid
particl
littl
surfac
charg
sempl
et
al
past
sever
year
signific
improv
potenc
lnpsirna
achiev
vari
chemic
structur
ioniz
cation
lipid
note
figur
progress
dodap
dodma
dlinkdma
shown
lipid
identifi
use
vivo
screen
model
employ
lnp
system
contain
sirna
silenc
factor
vii
fvii
one
protein
bloodclot
cascad
factor
vii
made
hepatocyt
secret
circul
thu
potenc
lnpsirna
system
monitor
earli
cation
lipid
dotma
dodac
contain
perman
posit
quaternari
amin
headgroup
ioniz
cation
lipid
tertiari
amin
headgroup
appar
pka
less
seven
allow
encapsul
nucleic
acid
perform
acid
ph
ph
result
lnp
exhibit
net
neutral
charg
physiolog
ph
measur
fvii
level
circul
h
iv
administr
lnp
remark
potenc
lnpsirna
system
improv
mg
sirnakg
bodi
weight
result
gene
silenc
lnp
contain
dodap
mg
sirnakg
bodi
weight
lnp
contain
jayaraman
et
al
sempl
et
al
improv
potenc
attribut
use
ioniz
cation
lipid
optim
pka
valu
maxim
bilay
destabil
capabl
given
presenc
anion
lipid
exist
within
endosom
pka
current
potent
ioniz
cation
lipid
hepat
gene
silenc
vivo
jayaraman
et
al
type
peg
lipid
also
influenc
potenc
lnpsirna
system
peg
lipid
incorpor
lnpsirna
formul
prevent
particl
aggreg
formul
process
peg
moieti
provid
hydrophil
steric
barrier
particl
surfac
maurer
fensk
culli
without
peglipid
coat
imposs
produc
small
lnpsirna
system
diamet
less
nm
larg
micron
size
aggreg
instead
form
although
peg
coat
import
form
small
stabl
particl
also
inhibit
lnp
associ
plasma
membran
target
cell
indic
need
remov
coat
cellular
uptak
proceed
one
potenti
solut
use
acidlabil
peg
lipid
peg
moieti
dissoci
lipid
anchor
low
ph
choi
mackay
szoka
guo
szoka
shin
shum
thompson
howev
ph
requir
low
ph
exist
extracellular
medium
thu
peg
lipid
remain
lnp
surfac
prevent
close
associ
cell
membran
anoth
approach
use
peg
lipid
dissoci
lnp
circul
follow
iv
administr
length
lipid
chain
anchor
peg
lipid
influenc
long
stay
liposom
parr
ansel
choi
culli
longer
acyl
chain
show
longer
retent
time
shorter
counterpart
recent
shown
peg
lipid
short
c
acyl
chain
dissoci
lnpsirna
vivo
halftim
approxim
h
mui
et
al
wherea
peg
lipid
longer
c
acyl
chain
exhibit
dissoci
rate
day
longer
offer
possibl
employ
lnp
stabil
peg
lipid
short
acyl
chain
rapidli
dissoci
follow
iv
administr
allow
lnpsirna
system
becom
potent
transfect
agent
addit
cation
lipid
peg
lipid
lnp
formul
sirna
typic
contain
structur
lipid
commonli
use
lipid
cholesterol
satur
phosphatidylcholin
pc
distearoylpc
dspc
dipalmitoylpc
dppc
reason
lipid
requir
unclear
cholesterol
includ
histor
data
bilay
liposom
system
indic
liposom
consist
pc
alon
accumul
cholesterol
serum
compon
rodrigueza
pritchard
hope
consequ
system
contain
approxim
equimolar
cholesterol
better
equilibrium
surround
need
dspc
counterintuit
presenc
dspc
would
expect
mitig
fusion
endosom
membran
follow
uptak
target
cell
due
strong
bilayerstabil
properti
culli
hope
tilcock
howev
recent
data
group
suggest
elimin
dspc
compromis
gene
silenc
potenc
lnpsirna
system
reason
yet
determin
unpublish
data
extens
work
well
incorpor
target
ligand
lnp
system
target
moieti
antibodi
fragment
small
molecul
ligand
coupl
onto
surfac
lnp
hope
increas
cellular
uptak
lnp
target
tissu
receptormedi
endocytosi
allen
culli
sapra
allen
report
liposom
monoclon
antibodi
fragment
show
better
cellular
uptak
breast
cancer
xenograft
compar
nontarget
liposom
kirpotin
et
al
also
antibodybear
liposom
contain
antisens
oligonucleotid
viral
mrna
show
better
efficaci
viral
infect
compar
liposom
without
antibodi
leonetti
machi
degol
lebleu
leserman
addit
use
antibodi
target
moieti
small
molecul
also
coupl
peg
lipid
enhanc
lnp
uptak
cell
subsequ
gene
silenc
activ
exampl
anisamid
small
compound
interact
sigma
receptor
increas
gene
silenc
activ
sirna
nanoparticl
lung
tumor
metastas
li
huang
li
chono
huang
addit
shown
strophanthidin
cardiac
glycosid
bind
ubiquit
express
cell
surfac
receptor
na
k
atpas
enhanc
deliveri
lnpsirna
cell
origin
number
tissu
prostat
ovari
breast
lung
pancrea
mani
case
target
moieti
conjug
distal
end
peg
lipid
result
target
lipid
ad
along
rest
lipid
compon
formul
process
altern
target
lipid
ad
stabl
preform
lnp
process
call
postinsert
iden
allen
use
postinsert
techniqu
prevent
target
lipid
interf
formul
process
provid
rel
simpl
method
prepar
target
lnp
formul
similar
develop
cation
lipid
formul
technolog
sirna
often
design
deliveri
plasmid
dna
later
adopt
sirna
formul
use
felgner
cowork
felgner
et
al
cellular
transfect
simpl
mixtur
dotma
dioleoylphosphatidylethanolamin
dope
togeth
form
complex
lipoplex
plasmid
dna
lipoplex
often
micron
diamet
unstabl
difficult
reproduc
often
formul
excess
cation
charg
promot
interact
plasmid
dna
also
facilit
associ
neg
charg
cell
surfac
subsequ
uptak
endocytosi
stamatato
et
al
incorpor
helper
lipid
dope
thought
facilit
releas
plasmid
dna
cytoplasm
due
propens
adopt
nonbilay
membran
lytic
hexagon
h
ii
phase
culli
de
kruijff
despit
intens
effort
howev
lipoplex
proven
use
vivo
applic
chief
reason
shortcom
highli
toxic
due
posit
charg
quickli
remov
circul
fix
free
macrophag
mp
due
size
charg
result
distribut
effici
target
cell
tumor
cell
difficulti
led
attempt
encapsul
nucleic
acid
within
enclos
bilay
membran
exhibit
low
surfac
charg
stabil
antisens
lipid
particl
method
solut
lipid
ethanol
ad
aqueou
solut
nucleic
acid
ph
sempl
et
al
rel
low
ph
buffer
ensur
ioniz
cation
lipid
propan
dodap
pka
posit
charg
interact
nucleic
acid
vesicl
subsequ
extrud
polycarbon
membran
ensur
uniform
size
distribut
dialysi
buffer
ph
remov
residu
ethanol
mixtur
deproton
ioniz
cation
lipid
creat
rel
neutral
system
prolong
circul
lifetim
figur
encapsul
effici
particl
diamet
nm
achiev
method
sempl
et
al
interestingli
result
particl
mainli
unilamellar
low
nucleic
acidtolipid
ratio
adopt
multilamellar
configur
higher
nucleic
acidtolipid
ratio
observ
led
suggest
nucleic
acid
bridg
individu
lipid
vesicl
promot
format
multilamellar
structur
variat
ethanoldrop
method
preform
vesicl
pfv
method
pfv
contain
dodap
cholesterol
dspc
peg
lipid
low
ph
typic
ph
dodap
proton
prepar
extrus
presenc
ethanol
figur
extrus
usual
rapid
presenc
ethanol
solut
nucleic
acid
ph
slowli
ad
ethanoldestabil
liposom
avoid
particl
aggreg
mixtur
incub
h
allow
encapsul
nucleic
acid
ethanol
remov
dialysi
encapsul
step
ph
solut
lipid
vesicl
first
produc
dropwis
addit
ethanol
solut
lipid
aqueou
buffer
follow
extrus
aqueou
solut
nucleic
acid
ad
slowli
result
vesicl
solut
usual
contain
approxim
ethanol
mixtur
incub
h
allow
encapsul
take
place
residu
ethanol
remov
dialysi
ph
solut
rais
method
usual
result
multilamellar
particl
approxim
nm
diamet
encapsul
effici
approxim
adjust
creat
charg
neutral
system
method
gener
multilamellar
particl
approxim
nm
diamet
nucleic
acid
encapsul
effici
suggest
attach
nucleic
acid
onto
surfac
extrud
liposom
creat
adhes
point
liposom
facilit
format
multilamellar
vesicl
also
explain
high
nucleic
acid
encapsul
effici
achiev
method
nucleic
acid
appear
entrap
lamella
multilamellar
particl
altern
method
extrus
spontan
vesicl
format
svf
ethanol
dilut
method
jeff
et
al
similar
mani
method
encapsul
method
first
develop
plasmid
dna
later
adopt
encapsul
sirna
method
nucleic
acid
prepar
acid
buffer
cation
lipid
dspc
cholesterol
peg
lipid
dissolv
ethanol
nucleic
acid
lipid
mixtur
combin
use
ttube
mixer
flow
two
stream
fluid
control
via
peristalt
pump
figur
jeff
et
al
vesicl
form
spontan
lipid
precipit
solut
polar
medium
rais
residu
ethanol
final
mixtur
remov
dialysi
sirna
encapsul
method
use
low
amount
peg
lipid
typic
rang
mol
lipid
result
particl
rang
nm
diamet
judg
bola
lee
maclachlan
zimmermann
et
al
encapsul
sirna
highli
effici
effici
routin
achiev
result
lnpsirna
term
stabl
nucleic
acid
lipid
particl
limit
ttube
mixer
formul
includ
difficulti
appli
process
laboratori
scale
formul
due
high
flow
rate
need
achiev
rapid
mix
limit
mix
rate
result
inabl
formul
lnp
lipid
composit
requir
rapid
mix
achiev
stabl
system
culli
laboratori
develop
inlin
mix
method
employ
microfluid
herringbon
micromix
herringbon
micromix
two
inlet
one
ethanol
mixtur
lipid
buffer
solut
sirna
ph
dual
syring
pump
use
drive
two
stream
fluid
herringbon
micromix
figur
two
stream
fluid
meet
herringbon
micromix
fold
wrap
around
exponenti
decreas
diffus
length
two
stream
allow
rapid
mix
two
stream
fluid
millisecond
timescal
rapid
decreas
solvent
polar
result
precipit
lipid
accord
solubl
techniqu
result
greater
sirna
encapsul
effici
wide
rang
sirnatolipid
ratio
cryotransmiss
electron
microscopi
indic
lnpsirna
produc
microfluid
mix
exhibit
electron
dens
core
similar
one
produc
ttube
inlin
mix
figur
addit
biochem
character
strongli
suggest
solid
electron
dens
core
compris
distort
invert
micel
cation
lipid
complex
encapsul
sirna
furthermor
molecular
dynam
simul
lnpsirna
system
suggest
particl
contain
nanostructur
hydrophob
core
sirna
surround
invert
micel
ioniz
cation
lipid
figur
result
consist
initi
condens
method
also
commonli
refer
ttube
method
involv
mix
lipid
compon
dissolv
ethanol
nucleic
acid
aqueou
buffer
use
ttube
connector
flow
two
stream
fluid
control
peristalt
pump
particl
form
ethanol
dilut
solubl
limit
lipid
ethanol
content
dilut
upon
exit
ttube
connector
stabil
result
particl
unencapsul
nucleic
acid
remov
use
ion
exchang
column
residu
ethanol
remov
diafiltr
phosphat
buffer
salin
pb
method
use
encapsul
plasmid
dna
stabil
plasmidlipid
particl
antisens
oligonucleotid
sirna
stabl
nucleic
acid
lipid
particl
invert
micel
ioniz
cation
lipid
around
sirna
serv
nucleat
structur
rest
lipid
assembl
solid
core
lnp
figur
hydrophil
lipid
peg
lipid
would
last
compon
deposit
nascent
lnp
thu
provid
outer
shell
stabil
particl
figur
result
also
consist
peg
lipid
last
compon
deposit
nascent
lnp
provid
outer
shell
stabil
particl
figur
base
model
one
would
expect
size
result
lnp
dictat
ratio
core
lipid
surfac
lipid
lipid
mix
inde
size
particl
freeli
adjust
nm
diamet
simpli
alter
peglipid
content
formul
comparison
pfv
techniqu
microfluid
mix
result
higher
encapsul
effici
gener
smaller
particl
permit
small
scale
product
littl
loss
due
dead
volum
method
allow
welldefin
reproduc
mix
solut
lipid
sirna
result
lower
batchtobatch
variat
method
employ
herringbon
micromix
facilit
mix
lipid
compon
dissolv
ethanol
sirna
aqueou
buffer
flow
two
stream
fluid
control
use
dual
syring
pump
herringbon
micromix
exponenti
increas
surfac
area
two
stream
fluid
result
rapid
mix
millisecond
timescal
residu
ethanol
remov
dialysi
ph
solut
rais
method
result
sirna
encapsul
effici
particl
size
adjust
nm
vari
peglipid
content
abovement
exampl
formul
reli
ioniz
cation
lipid
condens
sirna
encapsul
lnp
altern
lipidco
calcium
phosphat
lcp
nanoparticl
util
calcium
phosphat
condens
sirna
encapsul
lipid
layer
develop
li
chen
tseng
mozumdar
huang
fabric
process
involv
combin
calcium
chlorid
sodium
phosphat
sirna
solut
form
reversedphas
waterinoil
microemuls
figur
aqueou
sodium
citrat
ad
emuls
form
calcium
phosphat
precipit
entrap
sirna
calcium
phosphat
precipit
purifi
use
silica
gel
combin
liposom
made
perman
charg
cation
lipid
propan
dotap
cholesterol
form
lcp
nanoparticl
figur
lcp
formul
later
modifi
includ
anion
lipid
dioleoylphosphatid
acid
dopa
serv
inner
leaflet
lipid
coat
calcium
phosphat
precipit
electron
micrograph
dopa
coat
calcium
phosphat
show
hollow
core
approxim
nm
diamet
consist
hypothesi
neg
charg
dopa
headgroup
interact
posit
charg
calcium
phosphat
core
way
acyl
chain
dopa
face
exterior
particl
form
invert
micellelik
structur
lipid
compon
reach
individu
solubl
limit
precipit
solut
ethanol
lipid
stream
dilut
aqueou
stream
acid
sodium
acet
buffer
proton
ioniz
cation
lipid
blue
form
invert
micel
around
sirna
red
via
electrostat
interact
polar
solvent
increas
invert
micel
begin
aggreg
follow
coat
peg
lipid
purpl
form
lnpsirna
see
color
plate
surfac
particl
coat
varieti
surfac
lipid
adjust
surfac
charg
final
lcp
posit
neg
addit
peg
lipid
includ
prolong
circul
lifetim
result
lcp
nanoparticl
sirna
encapsul
effici
lcp
nanoparticl
typic
particl
size
approxim
nm
diamet
includ
peg
coat
lcp
nanoparticl
construct
cation
lipid
dotap
anisamid
target
peg
lipid
demonstr
efficaci
inhibit
lung
metastasi
melanoma
mous
model
yang
li
liu
huang
figur
prepar
lipidco
calcium
phosphat
lcp
nanoparticl
method
consist
first
prepar
solut
contain
calcium
chlorid
sirna
dispers
cyclohexaneigep
oil
well
solut
dioleoylphosphatid
acid
dopa
sodium
phosphat
dibas
ph
similarli
dispers
cyclohexaneigep
oil
two
solut
mix
min
calcium
phosphat
core
contain
sirna
isol
centrifug
follow
wash
ethanol
mixtur
outer
lipid
contain
dotap
cholesterol
peg
lipid
ad
core
resuspend
chloroform
chloroform
later
remov
evapor
result
lcp
nanoparticl
solut
resuspend
aqueou
buffer
nanoparticl
contain
three
differ
sirna
sequenc
target
cmyc
vegf
order
achiev
greater
therapeut
effect
inhibit
multipl
pathway
simultan
mice
treat
target
lcp
particl
shown
significantli
improv
surviv
rate
markedli
reduc
number
lung
metastat
nodul
compar
either
control
mice
mice
treat
lcp
without
anisamid
target
ligand
addit
lcp
technolog
use
coencapsul
sirna
gemcitabin
nucleosid
analog
use
firstlin
chemotherapeut
advanc
nonsmal
cell
lung
carcinoma
zhang
schwerbrock
roger
kim
huang
mechan
action
lcp
nanoparticl
still
investig
howev
hypothes
acid
environ
insid
endosom
dissolv
calcium
phosphat
core
particl
caus
increas
endosom
osmot
pressur
eventu
break
endosom
releas
sirna
cytoplasm
li
et
al
import
note
dival
cation
calcium
magnesium
known
induc
membranedisrupt
hexagon
h
ii
phase
membran
contain
anion
lipid
one
found
endosom
membran
hope
walker
culli
tilcock
culli
possibl
calcium
releas
lcp
particl
induc
hexagon
h
ii
phase
anion
lipid
endosom
membran
therebi
disrupt
integr
endosom
membran
facilit
intracellular
releas
encapsul
sirna
recent
advanc
lipidbas
formul
technolog
led
numer
lnpsirna
formul
variou
stage
clinic
trial
one
advanc
formul
alnylam
pharmaceut
cambridg
current
phase
iii
clinic
trial
treatment
transthyretin
ttr
amyloidosi
nonhuman
primat
shown
caus
decreas
serum
ttr
level
day
singl
iv
dose
mg
sirnakg
bodi
weight
coelho
et
al
anim
receiv
singl
mgkg
dose
sirna
suppress
serum
ttr
level
observ
day
lnpsirna
inject
similarli
human
author
observ
knockdown
ttr
level
day
singl
mgkg
dose
sirna
reduct
protein
level
day
coelho
et
al
suppress
serum
ttr
level
specif
sirna
target
unrel
protein
effect
serum
ttr
level
furthermor
formul
well
toler
minor
infusionrel
reaction
liver
kidney
toxic
anoth
promis
formul
alnylam
pharmaceut
alnpc
design
specif
target
proprotein
convertas
subtilisinkexin
type
produc
liver
treatment
hypercholesterolemia
mice
lack
shown
increas
express
ldlr
liver
decreas
level
cholesterol
plasma
rashid
et
al
knockdown
nonhuman
primat
lnpsirna
shown
lower
serum
ldl
cholesterol
level
increas
express
ldlr
liver
frankkamenetski
et
al
recent
phase
clinic
trial
singl
dose
alnpc
mg
sirnakg
bodi
weight
caus
decreas
serum
level
day
inject
fitzgerald
et
al
consequ
result
reduct
serum
ldl
cholesterol
level
requir
day
recov
pretreat
level
similar
formul
alnpc
well
toler
addit
target
intrins
protein
bodi
lnpsirna
technolog
also
activ
pursu
therapeut
viral
infect
tekmira
pharmaceut
burnabi
bc
recent
launch
phase
clinic
studi
tkmebola
lnpsirna
formul
treatment
infect
zair
strain
ebola
viru
zebov
formul
produc
use
ttube
inlin
mix
techniqu
mention
contain
three
differ
sirna
sequenc
target
l
polymeras
viral
protein
viral
protein
zebov
geisbert
et
al
preclin
studi
util
nonhuman
primat
anim
challeng
zebov
intramuscular
inocul
surviv
infect
follow
seven
daili
dose
tkmebola
mg
sirnakg
bodi
weight
per
dose
investig
unabl
detect
zebov
treat
anim
day
control
anim
treat
lnpsirna
formul
unrel
sirna
luciferas
succumb
viral
infect
day
viral
inocul
tkmebola
grant
fast
track
design
us
food
drug
administr
fda
march
although
lnpsirna
system
current
advanc
sirna
deliveri
technolog
clinic
trial
lipoplex
lipid
sirna
also
activ
clinic
investig
mean
deliv
therapeut
sirna
vivo
one
formul
silenc
therapeut
gmbh
berlin
germani
lipoplex
formul
target
protein
kinas
treatment
advanc
solid
tumor
aleku
et
al
formul
contain
polycation
lipid
prepar
method
similar
pfv
method
describ
santel
et
al
one
import
differ
pfv
method
lack
ethanol
formul
process
ethanol
import
factor
facilit
encapsul
sirna
allow
remodel
pfv
multilamellar
vesicl
membran
bridg
togeth
electrostat
interact
sirna
without
ethanol
formul
like
complex
cation
liposom
link
togeth
sirna
surfac
regardless
formul
procedur
effect
silenc
mrna
level
lung
liver
mice
follow
tail
vein
inject
four
daili
dose
mg
sirnakg
per
dose
aleku
et
al
formul
success
reduc
volum
xenograft
tumor
prostat
lower
amount
metastat
tumor
lymph
node
mice
compani
current
conduct
phase
ibiia
clinic
trial
combin
gemcitabin
treatment
advanc
pancreat
cancer
interestingli
local
lung
follow
iv
administr
prompt
compani
develop
lipoplex
formul
dacc
treat
lung
metastas
fehr
et
al
effect
reduct
express
lung
tumor
increas
surviv
rate
observ
mous
model
lung
metastas
inject
via
tail
vein
dacc
complex
sirna
fehr
et
al
remain
seen
whether
formul
would
advanc
clinic
test
treatment
lung
metastas
mention
tremend
effort
invest
design
ioniz
cation
lipid
maxim
gene
silenc
capabl
lnpsirna
jayaraman
et
al
sempl
et
al
although
hepat
gene
silenc
result
lnpsirna
contain
new
gener
ioniz
cation
lipid
greatli
improv
compar
system
made
earlier
gener
lipid
recent
studi
suggest
intracellular
releas
sirna
current
lnpsirna
system
highli
ineffici
process
follow
uptak
lnpsirna
cell
via
endocytosi
total
sirna
releas
cytosol
within
small
window
time
lnpsirna
accumul
specif
endocyt
compart
earli
late
endosom
characterist
gilleron
et
al
addit
author
detect
major
disrupt
endosom
membran
anoth
recent
report
intracellular
traffick
lnpsirna
system
reveal
approxim
intern
particl
eventu
exit
cell
recycl
mechan
depend
protein
niemannpick
type
sahay
et
al
cell
lack
gene
shown
reduc
endosom
recycl
activ
late
endosom
lysosom
extracellular
medium
result
cell
retain
lnpsirna
follow
endocytosi
show
potent
gene
silenc
wildtyp
cell
therefor
possibl
improv
gene
silenc
potenc
lnpsirna
system
manipul
endocyt
pathway
increas
intracellular
accumul
lnpsirna
andor
releas
sirna
cytosol
coincident
cellular
entri
ebola
viru
also
requir
function
treatment
cell
small
molecular
inhibitor
greatli
attenu
infect
viru
carett
et
al
et
al
small
molecul
inhibitor
use
conjunct
lnpsirna
inhibit
lnpsirna
recycl
thu
enhanc
bioavail
intern
sirna
gene
silenc
potenc
incorpor
metal
nanoparticl
lnpsirna
system
may
offer
attract
method
disrupt
endosom
membran
excit
metal
nanoparticl
embed
lipid
membran
light
radiat
magnet
field
possibl
increas
temperatur
lipid
membran
geltoliquid
crystal
phase
transit
temperatur
permeabl
membran
greatest
liposom
gold
nanoparticl
embed
membran
shown
releas
aqueou
content
follow
irradi
ultraviolet
light
paasonen
et
al
addit
gold
metal
nanoparticl
iron
oxid
util
gener
thermosensit
liposom
amstad
et
al
formul
gold
nanoparticl
liposom
prepar
sever
differ
method
reversephas
evapor
gold
nanoparticl
suspend
organ
phase
hong
friend
glabe
papahadjopoulo
paasonen
et
al
physic
adsorpt
gold
nanoparticl
onto
surfac
liposom
kojima
hirano
yuba
harada
kono
postinsert
gold
nanoparticleconjug
phospholipid
onto
preform
liposom
chithrani
dunn
stewart
allen
jaffray
embed
gold
nanoparticl
dri
lipid
film
follow
hydrat
park
oh
mun
han
recent
laboratori
demonstr
encapsul
gold
nanoparticl
lnp
mix
commonli
use
lipid
lnpsirna
formul
commerci
avail
neg
charg
gold
nanoparticl
microfluid
mixer
unpublish
method
straightforward
ioniz
cation
lipid
bind
neg
charg
gold
nanoparticl
manner
similar
encapsul
sirna
use
method
lnp
encapsul
iron
oxid
nanoparticl
potenti
possibl
modifi
function
group
carboxyl
acid
silica
render
surfac
neg
charg
laurent
et
al
thermosensit
lnpsirna
system
gener
coencapsul
metal
nanoparticl
sirna
use
ioniz
cation
lipid
enhanc
releas
sirna
follow
cellular
uptak
may
made
possibl
excit
cell
tissu
ultraviolet
light
altern
magnet
field
gener
enough
heat
disrupt
permeabil
endosom
membran
addit
potenti
benefit
enhanc
endosom
releas
sirna
metal
nanoparticl
coencapsul
sirna
lnp
system
also
serv
contrast
agent
bioimag
gold
nanoparticl
good
absorb
xray
radiat
shown
provid
therapeut
effect
tumorbear
mice
radiotherapi
enhanc
contrast
tumor
xray
imag
hainfeld
slatkin
smilowitz
hainfeld
slatkin
focella
smilowitz
hainfeld
smilowitz
oconnor
dilmanian
slatkin
howev
use
gold
nanoparticl
radiat
medicin
bioimag
suffer
poor
accumul
gold
nanoparticl
tumor
rapid
excret
kidney
follow
iv
inject
hainfeld
et
al
thu
lnp
carrier
system
potenti
improv
accumul
metal
nanoparticl
tumor
site
aforement
epr
effect
coencapsul
sirna
metal
nanoparticl
therefor
gener
lnp
system
dual
function
allow
bioimag
tumor
silenc
target
gene
therapeut
purpos
anticip
theranost
system
would
tremend
impact
biomed
applic
lnp
technolog
ioniz
cation
lipidbas
encapsul
technolog
sirna
describ
fulli
applic
nucleic
acid
polym
plasmid
mrna
major
challeng
lnpplasmid
system
suffici
target
gene
express
sinc
nuclear
envelop
remain
barrier
transloc
plasmid
dna
nucleu
effici
transgen
express
usual
observ
rapidli
divid
cell
nuclear
envelop
disintegr
mitosi
allow
plasmid
dna
enter
nucleu
balli
et
al
mortim
et
al
contrast
mrnalnp
system
elimin
need
nuclear
transloc
gene
express
hecker
zou
scarfo
nantz
hecker
shown
mrna
deliv
electropor
result
express
target
gene
van
tendeloo
et
al
therapeut
potenti
mrna
demonstr
fact
chemic
modifi
mrna
mediat
express
target
protein
spb
lung
follow
intratrach
administr
spb
defici
mice
kormann
et
al
howev
mani
tissu
inaccess
local
administr
lnpmrna
system
allow
system
deliveri
particular
potenc
tissu
liver
hepatocyt
recent
demonstr
chemic
modifi
mrna
condens
protamin
encapsul
insid
preform
cation
vesicl
microfluid
mix
method
present
previous
would
elimin
need
nucleic
acidcondens
agent
protamin
need
timeconsum
extrus
process
lnpmrna
system
produc
microfluid
mix
would
contain
lipid
compon
use
deliveri
sirna
expect
lnpmrna
would
display
biodistribut
pharmacokinet
properti
similar
lnpsirna
system
abil
system
deliv
mrna
consider
potenti
treatment
cancer
varieti
genet
disord
anoth
genet
materi
benefit
lipidbas
deliveri
therapeut
purpos
recent
discov
cluster
regularli
interspac
short
palindrom
repeat
crispr
crispr
origin
discov
escherichia
coli
subsequ
recogn
import
adapt
immun
pathway
found
bacteria
archaea
ishino
shinagawa
makino
amemura
nakata
marraffini
sontheim
mechan
bacteri
adapt
immun
crispr
review
extens
elsewher
marraffini
sontheim
rusk
sorek
kunin
hugenholtz
water
storz
wiedenheft
sternberg
doudna
recent
interest
crispr
technolog
stem
possibl
use
crispr
modifi
gene
order
tackl
human
diseas
crispr
along
endonucleas
crisprassoci
protein
facilit
genom
edit
introduc
doublestrand
break
specif
genet
locu
sequenc
complementari
guid
rna
grna
jinek
et
al
jinek
et
al
gene
therefor
delet
replac
use
novel
technolog
crispr
system
use
produc
genet
modifi
anim
numer
speci
includ
fruit
fli
zebrafish
rabbit
rat
mous
review
sander
joung
genet
modifi
mice
produc
inject
mrna
encod
endonucleas
along
guid
rna
grna
target
gene
modifi
mous
embryo
crispr
system
also
use
correct
diseasecaus
mutat
cataractfre
mice
gener
inject
mrna
grna
target
mutat
crygc
gene
locu
mous
zygot
follow
implant
surrog
femal
mice
wu
et
al
also
mutat
cystic
fibrosi
transmembran
conductor
receptor
cftr
intestin
stem
cell
cystic
fibrosi
patient
correct
crispr
ca
system
use
grna
target
mutat
cftr
locu
along
plasmid
dna
encod
correct
cftr
sequenc
templat
homologydirect
repair
schwank
et
al
preliminari
exampl
support
crisprmedi
genet
modif
novel
strategi
treat
genet
diseas
proper
genet
modif
crispr
requir
least
two
compon
introduc
target
cell
first
grna
specif
genet
locu
modifi
second
endonucleas
usual
introduc
plasmid
vector
mrna
cell
modifi
contain
homozyg
mutat
gene
addit
plasmid
encod
correct
version
gene
necessari
order
facilit
homologydirect
repair
mutat
obviou
nucleic
acid
requir
effici
method
enter
target
cell
exampl
crisprmedi
genet
modif
mention
use
either
commerci
avail
transfect
reagent
viral
vector
direct
inject
crispr
compon
target
cell
inferior
vivo
perform
compar
lipidbas
deliveri
system
clear
understand
crisprca
system
still
earli
stage
howev
numer
compani
begun
aggress
program
develop
research
tool
crispr
field
review
baker
race
first
crisprbas
therapeut
genet
diseas
current
underway
much
like
develop
sirnabas
drug
year
ago
develop
effect
deliveri
system
crispr
compon
key
race
base
proven
track
record
nucleic
acid
deliveri
possibl
lipidbas
system
forefront
crispr
technolog
remain
seen
whether
crispr
technolog
enjoy
much
success
sirna
clinic
certain
see
mani
innov
formul
method
deliveri
materi
crispr
near
futur
